Categories: DeliveryMarketMedtech
Founded by recognized leaders in intrathecal therapies, CNS Therapeutics developed and brought to market safe, high-quality pharmaceuticals for site-specific delivery to the central nervous system. CNS was acquired by Covidien in 2012.
Investors 1
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.01.2011 | - | $3M | - |
| 27.08.2009 | - | $7M | - |
Mentions in press and media 4
| Date | Title | Description |
| 10.01.2011 | Minnesota drug developer CNS Therapeutics raises $3 million | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 27.08.2009 | Minnesota’s CNS Therapeutics raises $7 million | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R... |
| - | Minnesota’s CNS Therapeutics raises $7 million | WOODBURY, Minnesota — The early-stage pharmaceutical company CNS Therapeutics has raised $7 million, according to a filing with the Securities and Exchange Commission.
Not much is known about the 2-year-old company and CNS President John Fo... |
| - | Minnesota drug developer CNS Therapeutics raises $3 million | On the heels of FDA approval of its new anti-spasticity drug Gablofen, CNS Therapeutics has raised $3 million in equity, according to documents filed with the Securities and Exchange Commission.
Gablofen (baclofen) is administered to the ce... |
Reviews 0
